Regeneron Pharmaceuticals applies to US FDA for Emergency Use Authorization for its antibody ‘cocktail’ against COVID-19

REGEN-COV-2 is made up of two antibodies that bind non-competitively to the receptor binding domain of the virus’s spike protein, protecting against spike variants that have evolved in the human population. It is currently in Phase III trials.

Source:

Biospace Inc.